Stemcells, Inc.

Palo Alto, CA 94303

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $2.11MM
First Award Date 05/01/00
Most Recent Award Date 03/01/10

Key Personnel

Last Name Name Awards Contact
Lagasse Eric Lagasse 2
Carlson George A. Carlson 2
Uchida Nobuko Uchida 3
Glenn Jeffrey S Glenn 2
Millan Maria T Millan 2

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-397
Budget: 03/01/10 - 01/31/12

DESCRIPTION (provided by applicant): We propose to carry out foundational studies to characterize the Hepatitis C infectivity of candidate human liver cell transplant products. In order to achieve these studies, we propose to a) assess the HCV infectivity of different fetal and adult liver cell populations, and 2) determine whether shRNA directe...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-97
Budget: 09/30/08 - 09/29/10

DESCRIPTION (provided by applicant): We propose to carry out foundational studies to characterize the Hepatitis C infectivity of candidate human liver cell transplant products. In order to achieve these studies, we propose to a) assess the HCV infectivity of different fetal and adult liver cell populations, and 2) determine whether shRNA directe...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 03/31/06

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive neurodegenerative disease. It is prevalent among the elderly, affecting approximately 4 million Americans. Alzheimer's is a heterogeneous disease involving a number of components, including genetics. Although the accumulation of beta-amyloid peptide (AB) has been asso...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 08/31/05

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive neurodegenerative disease. It is prevalent among the elderly, affecting approximately 4 million Americans. Alzheimer's is a heterogeneous disease involving a number of components, including genetics. Although the accumulation of beta-amyloid peptide (AB) has been asso...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/05/03 - 12/31/04

DESCRIPTION (provided by applicant): The objective of this grant is to investigate whether transplantation of human central nervous system stem cells (CNS-SC) can contribute to functional recovery of spinal cord injury (SCI). We created cell banks of human CNS-SC generated from prospective isolated human CNS-SC from fetal brain tissues. We have ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AI-00-08
Budget: 02/01/02 - 01/31/04

DESCRIPTION: This application proposes to use NOD/SCID mice transplanted (intrasplenically or under kidney capsule) with human hepatocytes for HCV infection. The project will first identify hepatocyte subpopulations that are most susceptible to HCV infection, and examine the possible effects of hepatocyte growth factor (HGF) on hepatocyte growth...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AI-00-08
Budget: 02/15/01 - 01/31/02

DESCRIPTION: This application proposes to use NOD/SCID mice transplanted (intrasplenically or under kidney capsule) with human hepatocytes for HCV infection. The project will first identify hepatocyte subpopulations that are most susceptible to HCV infection, and examine the possible effects of hepatocyte growth factor (HGF) on hepatocyte growth...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/12/00 - 02/11/01

The objectives of this grant are to test the engraftment potential and biological activity of expanded purified human central nervous system neural stem cells (CNS-NSC) in a rodent model for Parkinson's disease. Recently, we have shown the identification and direct isolation of human CNS-NSC from primary fetal tissues using monoclonal antibodies...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/00 - 10/31/00

Neural cell transplants hold promise for the treatment of some neurodegenerative disorders, however, a fundamental question remains on the optimal cell type for this approach. Recently, we have developed and used monoclonal antibodies (mAbs) directed toward surface markers on human neural cells to identify and purify neural stem cells (NSCs) by ...